DOWNLOAD THIS BOOK FREE HERE
The Third Edition of Handbook of Evidence-Based Radiation Oncology updates and revises the previous successful editions and serves as a key reference for radiation oncology professionals. Organized by body site, concise clinical chapters provide easy access to critical information. Important “pearls” of epidemiology, anatomy, pathology, and clinical presentation are highlighted. The key elements of the work-up are listed, followed by staging and/or risk classification systems. Treatment recommendations are discussed based on stage, histology, and/or risk classification. Brief summaries of key trials and studies provide the rationale for the recommendations. Practical guidelines for radiation techniques are described and complications and follow-up guidelines are outlined. The Third Edition incorporates new key studies and trials to reflect current radiation oncology practice; includes the most recent staging systems; and features new color illustrations and anatomic atlases to aid in treatment planning. This book is a valuable resource for students, resident physicians, fellows, and other practitioners of radiation oncology.
s more practical aspects of clinical research and biostatistics in oncology, instead of relying only on mathematical formulas and theoretical considerations. Methods and Biostatistics in Oncology will help readers develop the skills they need to understand the use of research on everyday oncology clinical practice for study design and interpretation, as well to demystify the use of EBM in oncology.
Raphael L. C. Araujo is a Surgical Oncologist specialized in the diagnosis and treatment of malignant and benign injuries of the liver, pancreas and colorectal liver metastases. He spent two years (2010 / 2012) as a Research Fellow at the Hepatopancreatobiliary Service of the Memorial Sloan-Kettering Cancer Center in New York (USA). During this time, he worked on clinical research of surgical and systemic treatment of pancreatic cancer and colorectal liver metastases. Afterwards, he also spent one year as a resident of the Hepatopancreatobiliary Service at the Hospital Paul Brousse, France (2012/2013). Dr. Araujo received a PhD and concluded his postdoctoral research in Gastroenterology from the University of São Paulo School of Medicine, the same institution where he worked for 2 years as an attending physician in the Liver Surgery Unit. He is currently head of the Department of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery and Professor of the Post Graduation Program of Barretos Cancer Hospital, Barretos, São Paulo, Brazil, and Scientific Director of Brazilian Society of Surgical Oncology.
Rachel P. Riechelmann is a medical oncologist and researcher in the field of gastrointestinal cancers. She completed her formal training and PhD at the Federal University of Sao Paulo, followed by a clinical research fellowship at Princess Margaret Hospital, University of Toronto, Canada. She is currently the Director of the Department of Oncology at AC Camargo Cancer Center, which is one of the largest academic cancer centers in Brazil and Latin America, and Research Director of the Brazilian Gastrointestinal Tumors Group. Research- wise, her areas of interest and expertise are GI malignancies and Neuroendocrine Tumors as well as Methodology of Clinical Research. She has 78 publications in peer-reviewed journals and several PhD students and oncology fellows conducting projects under her supervision.
Textbook of Lung Cancer, 2nd edition, published in association with the European Society of Medical Oncology, is a comprehensive and multidisciplinary text, which examines all aspects of this disease, with contributions from a multinational team of authors on etiology, epidemiology, molecular biology, pathology, smoking, detection and management, clinical features, staging and prognostic factors, surgery, radiotherapy and chemotherapy. It provides essential information and guidance for specialist trainees in oncology, and for the many physicians and specialists involved in the field of lung cancer.
Leading clinicians and expert researchers bring together under one cover a comprehensive guide to the newest and most essential molecular techniques-particularly PCR-for diagnosing and monitoring hematological and solid tumors. These distinguished practitioners demonstrate step-by-step the use of PCR, FISH, CGH, Southern analysis, sequencing, and SSCP to assess cancer markers, to detect minimal disease and apoptosis, and to uncover particular translocations, mutations, and deletions. Their readily reproducible results offer physicians and scientists a promising entré into the powerful possibilities of using these techniques to improve the diagnosis, prognosis, and management of cancer.
Over the past 20 years, technological advances in molecular biology have proven invaluable to the understanding of the pathogenesis of human cancer. The application of molecular technology to the study of cancer has not only led to advances in tumor diagnosis, but has also provided markers for the assessment of prognosis and disease progression. The aim of Molecular Ana- sis of Cancer is to provide a comprehensive collection of the most up-to-date techniques for the detection of molecular changes in human cancer. Leading researchers in the field have contributed chapters detailing practical pro- dures for a wide range of state-of-the-art techniques. Molecular Analysis of Cancer includes chapters describing techniques for the identification of chromosomal abnormalities and comprising: fluor- cent in situ hybridization (FISH), spectral karyotyping (SKY), comparative genomic hybridization (CGH), and microsatellite analysis. FISH has a pro- nent role in the molecular analysis of cancer and can be used for the detection of numerical and structural chromosomal abnormalities. The recently described SKY, in which all human metaphase chromosomes are visualized in specific colors, allows for the definition of all chromosomal rearrangements and marker chromosomes in a tumor cell. Protocols for the detection of chromosomal re- rangements by PCR and RT-PCR are described, as well as the technique of DNA fingerprinting, a powerful tool for studying somatic genetic alterations in tumorigenesis.
The accessible guide to the principles behind new, more targeted drug treatments for cancer
Written for anyone who encounters cancer patients, cancer data or cancer terminology, but have no more than a passing knowledge of cell biology. A Beginner’s Guide to Targeted Cancer Treatments provides an understanding of how cancer works and the many new treatments available.
Using over 100 original illustrations, this accessible handbook covers the biology and mechanisms behind a huge range of targeted drug treatments, including many new immunotherapies. Dr Vickers translates a complex and often overwhelming topic into something digestible and easily understood. She also explains what cancer is, how it behaves and how our understanding of cancer has changed in recent years.
Each chapter takes the reader through how new cancer drugs work and their benefits and limitations. With the help of this book, readers will be able to better understand more complex, in-depth articles in journals and books and develop their knowledge. This vital resource:
* Offers the latest insights into cancer biology
* Provides a broad understanding of how targeted cancer treatments work
* Describes many of the new immunotherapy approaches to cancer treatment, such as checkpoint inhibitors and CAR-modified T cells
* Helps readers feel confident discussing treatment options with colleagues and patients
* Provides an overview of which treatments are relevant to each of the most common solid tumours and haematological cancers, and the rationale behind them
* Demystifies the jargon – terms such as the EMT, cancer stem cells, monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors etc.
* Explains the resistance mechanisms to many new treatments, including issues such as the way cancer cells diversify and evolve and the complex environment in which they live
International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression
Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development.
A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.
Over the past decade, PET-CT has achieved great success owing to its ability to simultaneously image structure and function, and show how the two are related. More recently, PET-MRI has also been developed, and it represents an exciting novel option that promises to have applications in oncology as well as neurology. The first part of this book discusses the basics of these dual-modality techniques, including the scanners themselves, radiotracers, scan performance, quantitation, and scan interpretation. As a result, the reader will learn how to perform the techniques to maximum benefit. The second part of the book then presents in detail the PET-CT and PET-MRI findings in cancers of the different body systems. The final two chapters address the use of PET/CT in radiotherapy planning and examine areas of controversy. The authors are world-renowned experts from North America, Europe, and Australia, and the lucid text is complemented by numerous high-quality illustrations.
This book provides an overview of recent advances in radiation oncology, many of which have originated from physics and engineering sciences. After an introductory section on basic aspects of 3D medical imaging, the role of 3D imaging in the context of radiotherapy is explored in a series of chapters on the various modern imaging techniques. A further major section addresses 3D treatment planning for conformal radiotherapy, with consideration of both external radiotherapy and brachytherapy. Subsequently the modern techniques of 3D conformal radiotherapy are described, including stereotactic radiotherapy, intensity-modulated radiation therapy, image-guided and adaptive radiotherapy, and radiotherapy with charged particles. More clinically oriented chapters explore the use of brachytherapy in patients with prostate cancer, cardiovascular disorders and breast cancer. The book concludes with a section on quality assurance. The text is specifically designed to be accessible to professionals and students with a medical background as well as to newcomers to radiation oncology from the field of physics.